Skip to search boxSkip to navigationSkip to main content

Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis

  • Jennifer Chae-Kim(corresponding author)
    ,
  • Gunjal Garg
    ,
  • ,
  • Lindsay E. Blake
    ,
  • Tongil Kim
    ,
  • Qiang Wu
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objective Progestin therapy is the recommended fertility-sparing management of atypical endometrial hyperplasia or early-stage endometrial cancer in reproductive-aged women. Our objective was to evaluate disease relapse after progestin and metformin versus progestin therapy alone in patients with endometrial hyperplasia or cancer. Our secondary outcomes were disease remission, clinical pregnancy and live birth rate. Methods A systematic review of the literature was conducted (MEDLINE, Web of Science, Cochrane Library, CINAHL, LILACS, clinicaltrials.gov) from inception to April 2021. Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review. Early endometrial cancer was defined as grade 1, stage 1 disease. Exclusion criteria included women with higher grade endometrial cancer and when conservative management was not for fertility-sparing purposes. Data are presented as odds ratios (ORs) and 95% confidence intervals (CIs) with fixed or random effects meta-analysis. Quality scoring was based on the Newcastle-Ottawa and Jadad scales. Results In total, 271 reports were identified and six studies met the inclusion criteria. These studies included 621 women; 241 (38.8%) patients received combined therapy and 380 (61.2%) received progestin therapy alone. Relapse rates were lower for progestin and metformin than for progestin therapy alone (pooled OR 0.46, 95% CI 0.24 to 0.91, p=0.03). The remission rates were not different (pooled OR 1.35, 95% CI 0.91 to 2.00, p=0.14). Women who received progestin and metformin achieved pregnancy and live birth rates similar to those who received progestin therapy only (pooled OR 1.01, 95% CI 0.44 to 2.35, p=0.98; pooled OR 0.46, 95% CI 0.21 to 1.03, p=0.06). Conclusion For reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer, progestin and metformin therapy compared with progestin therapy alone is associated with lower relapse rates, and similar remission, clinical pregnancy and live birth rates.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1499-1505 (7 pages)

Journal (Volume, Issue Number)

International Journal of Gynecological Cancer (Volume 31, Issue 12)

Publication milestones

  • Published - 12/2021

Publication status

Published - 12/2021

ISSN

1048-891X

Publication IDs

  • Scopus: 85122546458
  • PubMed: 34785524

Publication metrics

Metrics

Fractional count
2
Fractional count
0.29
Fractional count
5
Fractional count
0.71
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
43
Captures
61

Funding Details

The authors would like to acknowledge the Departments of Obstetrics and Gynecology at Texas A&M College of Medicine, at Baylor Scott & White Health, and Brody School of Medicine at East Carolina University, and Vidant Medical Center for supporting this research.
FundersFunding numbers
Departments of Obstetrics and Gynecology at Texas A&M College of Medicine
-
Vidant Medical Center
-
Brody School of Medicine
-
BSWH
-